Globus Medical GMED has experienced strong upward momentum in the past year, with its shares rising 41.8%. This has far outpaced the industry’s 7.5% decline and the S&P 500 composite’s 8.8% growth.

HighTower Advisors LLC raised its stake in Globus Medical, Inc. (NYSE:GMED – Free Report) by 2.4% during the fourth quarter, ...

Globus Medical (NYSE:GMED – Get Free Report) was downgraded by investment analysts at StockNews.com from a “buy” rating to a “hold” rating in a report issued on Friday. Several other equities analysts ...

From novel pharmaceuticals to telemedicine, most healthcare companies are on a mission to drive better patient outcomes. But ...

Learn more about whether Globus Medical, Inc. or Lantheus Holdings, Inc. is a better investment based on AAII's A+ Investor ...

Globus Medical, Inc. (NYSE: GMED) will present its latest advancements in orthopedic technology at the 2025 Annual Meeting of the American Academy of Orthopedic Surgeons (AAOS), taking place ...

Learn more about whether Globus Medical, Inc. or QuidelOrtho Corporation is a better investment based on AAII's A+ Investor ...

Globus Medical, Inc. GMED continues to benefit from the robust demand for its Musculoskeletal Solutions products. Following the NuVasive merger, the combined company has formed a global ...

Truist analyst Richard Newitter lowered the firm’s price target on Globus Medical (GMED) to $82 from $90 and keeps a Hold rating on the shares.

Clearly, options traders are pricing in a big move for Globus Medical shares, but what is the fundamental picture for the company? Currently, Globus Medical is a Zacks Rank #3 (Hold) in the ...

In a report released today, Kallum Titchmarsh from Morgan Stanley maintained a Buy rating on Globus Medical (GMED – Research Report), with a ...